23.12.2008 Announcement no. 37-08 Page 1 of 1

NEUROSEARCH

NeuroSearch A/S Pederstrupvej 93 DK - 2750 Ballerup

Denmark

Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CV# No. DK-17 54 6166

Announcement

NeuroSearch announces financial calendar for 2009

NeuroSearch's financial calendar for 2009 is as follows:

4 March 2009: Annual Report 2008

29 April 2009: Annual General Meeting and first quarter report 2009

26 August 2009: Half year report 2009
11 November 2009: Third quarter report 2009

Thomas Hofman-Bang Chairman of the Board

Contacts:

Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdag OMX Copenhagen. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial share of its activities is partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with, among others, Abbott and Astellas. NeuroSearch's drug pipeline comprises 14 clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity and in Type 2 diabetes (prepared for Phase III), NS2359 for depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 for ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 for schizophrenia (Phase I) in partnership with Astellas, ACR325 for Parkinson's disease (Phase II in preparation) and bipolar disorder (Phase II in preparation). ABT-107 and ABT-560 for the treatment of various CNS disorders - both (Phase I) in collaboration with Abbott, NSD-644 for pain (Phase I) in partnership with GSK, ACR343 for Parkinson's disease (Phase I) and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.